Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases

Author(s): S. Mckenzie-Nickson, A. I. Bush, K. J. Barnham

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 27 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Pathological aggregation of endogenous proteins is a common feature of many neurodegenerative diseases. This is generally accompanied by elevated levels of oxidative stress associated with transition metal dyshomeostasis. As such, strategies targeted toward rectifying metal imbalance are increasingly becoming an attractive therapeutic option. One class of compound showing such therapeutic potential are the bis(thiosemicarbazone) metal complexes. These are small, orally bioavailable compounds capable of crossing the blood brain barrier and capable of delivering bioavailable metal intracellularly. Members of this family of compounds have been shown to successfully treat animal models of several neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Here we review the current evidence for the efficacy of bis(thiosemicarbazone) metal complexes in treating these diseases and discuss the implications for future development of these compounds.

Keywords: bis(thiosemicarbazone), BTSC, ALS, CuII(atsm), CUII(gtsm), AD.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 06 September, 2016
Page: [3058 - 3068]
Pages: 11
DOI: 10.2174/1568026616666160216155746
Price: $65

Article Metrics

PDF: 50
PRC: 1